Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provide informed consent~* Age ≥ 18 years and of either sex~* Willing to comply with protocol instructions, including allowing all study assessments~* Have a venous leg ulcer (VLU) between the knee and ankle (at or above the malleolus), with a surface area ≥ 4.0 cm x cm and ≤ 15.0 cm x cm~* Venous insufficiency confirmed by duplex Doppler ultrasound examination for valvular or venous incompetence~* Arterial supply adequacy confirmed~* Target ulcer involves a full thickness skin loss, but WITHOUT exposure of tendon, muscle, or bone~* Target ulcer duration ≥ 12 weeks but ≤ 104 weeks (24 months).~* Acceptable state of health and nutrition~Exclusion Criteria:~* History of anaphylaxis, serum sickness, or erythema multiforme reaction to aprotinin, bovine serum albumin or bovine serum proteins, penicillin, streptomycin, amphotericin B or any other component of HP802-247,or known sensitivity to Iodine~* Prior diagnosis of Systemic Lupus Erythematosus with elevated anti-DNA antibody titers, Buerger's disease (thromboangiitis obliterans), current diagnosis of vasculitis, or current diagnosis of claudication~* Therapy with another investigational agent within thirty (30) days of Screening, or during the study, or any participation in a previous HP802-247 trial~* A target ulcer of non-venous etiologies (e.g., sickle cell anemia, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, vasculopathic or vasculitic)~* Documented history of osteomyelitis at the target wound location within 6 months preceding the Screening Visit~* Refusal of or inability to tolerate compression therapy~* Therapy of the target ulcer with Collagenase Santyl® ointment, autologous skin graft, biological dressings or living cell products (e.g., Oasis®, Apligraf™, Dermagraft™) within 30 days preceding the Screening Visit~* Therapy of the target ulcer with topical growth factors within 1 week preceding the Screening Visit~* Current therapy with systemic antibiotics~* Current systemic therapy with cytotoxic drugs~* Current therapy with chronic (\> 10 days) oral corticosteroids~* Current therapy with TNFα inhibitors~* History of cancer in the preceding 5 years (other than carcinoma in situ of the cervix or adequately treated non-melanoma skin cancers)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HP802-247 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).